Pfizer's big blockbuster Xeljanz flunks its post-marketing safety study, renewing harsh questions for JAK class
When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study.
That study has since become a consistent headache for Pfizer and their blockbuster molecule. Last year, Pfizer dropped the entire high dose cohort after an independent monitoring board found more patients died in that group than in the low dose arm or a control arm of patients who received one of two TNF inhibitors, Enbrel or Humira.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,800+ biopharma pros reading Endpoints daily — and it's free.